Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | IL2 | P60568 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16062727 | 0.95 | TTR (0.43) | TTRIL2 | |
| SCHEMBL12342488 | 0.92 | TTR (0.46) | TTRIL2 | |
| SCHEMBL13684272 | 0.92 | TTR (0.46) | TTRIL2 | |
| SCHEMBL25559708 | 0.91 | TTR (0.45) | TTRIL2 | |
| SCHEMBL14129407 | 0.89 | TTR (0.45) | TTRIL2 | |
| SCHEMBL13402834 | 0.87 | TTR (0.46) | TTRIL2 | |
| SCHEMBL13540856 | 0.87 | TTR (0.45) | TTRIL2 | |
| SCHEMBL12020709 | 0.85 | TTR (0.43) | TTRIL2 | |
| SCHEMBL12020802 | 0.84 | TTR (0.42) | TTRIL2 | |
| SCHEMBL12377441 | 0.84 | TTR (0.46) | TTRIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7591994-B2 | Improved targetting | IMMUNOMEDICS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080166363-A1 | Improved targetting | IMMUNOMEDICS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166363-A1 | Improved targetting | CD47, CYTH3, FCGR2A | TTR 4273/4885IL2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.